TerminatedPhase 3

Phase 3 Study of Zandelisib (ME-401) in Combination With Rituximab in Patients With iNHL - (COASTAL)

Stopped: Discontinuation of zandelisib program

United States82 participantsStarted 2021-08-13

Plain-language summary

This is a Phase 3 study of the PI3Kδ inhibitor Zandelisib (ME-401) in combination with rituximab, in comparison to standard immunochemotherapy (Rituximab-Bendamustine or Rituximab-CHOP) in subjects with relapsed or refractory FL and MZL.

Who can participate

Age range18 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion criteria

✓. FL Gr 1, Gr 2, or Gr 3a
✓. MZL (splenic, nodal, or extra-nodal)

What they're measuring

Progression Free Survival

Timeframe: 1 year 7 months

Trial details

NCT IDNCT04745832

SponsorMEI Pharma, Inc.

Sponsor typeINDUSTRY

Study typeINTERVENTIONAL

Primary completion2023-03-20

Results submitted2023-10-02

View on ClinicalTrials.gov More Follicular Lymphoma (FL) trials